BEIJING KAWIN TECHNOLOGY SHARE-HOLDING CO., LTD. Beijing Kawin Technology Share-Holding Co., Ltd. Share Price
Equities
688687
CNE1000054C3
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.94 CNY | +2.11% |
|
+1.80% | -14.11% |
| 10/04 | China stocks down pressured by real estate; HK shares up | RE |
| 09/04 | Beijing Kawin Technology Share-Holding Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 1.71B 236M 19.69B | Sales 2025 * | 2.2B 303M 25.3B | Capitalization | 5.01B 692M 57.76B |
|---|---|---|---|---|---|
| Net income 2024 * | 148M 20.44M 1.71B | Net income 2025 * | 198M 27.35M 2.28B | EV / Sales 2024 * | 2.93 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.28 x |
| P/E ratio 2024 * |
34.7
x | P/E ratio 2025 * |
25.9
x | Employees | 584 |
| Yield 2024 * |
1.05% | Yield 2025 * |
1.5% | Free-Float | 69.27% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.11% | ||
| 1 week | +1.80% | ||
| 1 month | -6.70% | ||
| 3 months | +39.71% | ||
| 6 months | -1.58% | ||
| Current year | -14.11% |
1 week
29.10
30.88
1 month
23.6333.39
Current year
18.5035.79
1 year
18.5037.63
3 years
14.7638.13
5 years
14.7670.00
10 years
14.7670.00
| Managers | Title | Age | Since |
|---|---|---|---|
De Sheng Zhou
CEO | Chief Executive Officer | 53 | 01/08/01 |
Wei Guo
DFI | Director of Finance/CFO | 38 | 01/19/01 |
Yan Cui
BRD | Director/Board Member | 40 | 01/11/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jun Feng Wang
BRD | Director/Board Member | 50 | 01/11/01 |
Man Li Su
BRD | Director/Board Member | 54 | 12/21/12 |
De Sheng Zhou
CEO | Chief Executive Officer | 53 | 01/08/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 29.94 | +2.11% | 3,504,297 |
| 29/24/29 | 29.32 | -0.31% | 5,325,721 |
| 26/24/26 | 29.41 | +3.92% | 4,753,095 |
End-of-day quote Shanghai S.E., April 30, 2024
More quotes
Beijing Kawin Technology Share-Holding Co Ltd is a China-based company principally engaged in the production and sales of therapeutic drugs in the viral disease field, and the research and development of innovative drugs. The Company's recombinant human interferon α2b and compound glycyrrhizin drugs are applied to treat viral diseases. The Company mainly distributes its products within domestic market.
Calendar
22/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
29.94
CNY
Average target price
39.66
CNY
Spread / Average Target
+32.46%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.11% | 693M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- 688687 Stock
